OPEN LABEL EXTENSION OF PROTOCOL AALS-001 (#AALS-001-OL) - ARIMOCLOMOL IN AMY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是评估参加IIa期双盲研究(AALS-001)的ALS患者在6个月的治疗过程中服用阿莫氯莫尔的安全性和耐受性。次要目的是评价阿利莫洛尔对ALS患者ALSFRS-R和用力肺活量(FVC)的长期疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the safety and tolerability of arimoclomol over six months of treatment in patients with ALS who participated in the phase IIa double-blind study (AALS-001). The secondary objective is to evaluate the long-term effect of arimoclomol on the ALS-specific functional rating scale (ALSFRS-R) and forced vital capacity (FVC) in patients with ALS.